Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.

Gong J, Gao F, Jiang K, Xie Q, Zhao X, Lei Z

Journal of diabetes investigation21 Nov 2024Cited by 2 (Europe PMC)

PMID39569606PMCIDPMC11693576DOI10.1111/jdi.14340PepBankPUB-39569606

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewSafety outcome
In patients with type 2 diabetes or obesity, tirzepatide was associated with a higher risk of gallbladder/biliary diseases than comparators in a meta-analysis of randomized trials.
In plain wordsIn people with type 2 diabetes or obesity, tirzepatide was linked to more gallbladder and bile duct disease than placebo or other diabetes drugs.
Peptide
Tirzepatide
Outcome
IncreaseGallbladder/biliary diseases
Study
n = 12,351
Comparator
Placebo or other hypoglycemic drugs
Outcome group
Biliary adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
risk ratio
1.52 RR
gallbladder/biliary diseases
Source sentences
Summary
tirzepatide was associated with gallbladder/biliary diseases (RR = 1.52; 95%CI: 1.17-1.98; I² = 0%, P = 0.76)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled studies (RCTs) investigating the safety of tirzepatide vs placebo/other hypoglycemic drugs in patients with T2DM or obesity were included.
Summary · context
A total of 12 high-quality RCTs (involving 12,351 patients) were included.
Report a problemFND-3956960601
02HumanSystematic reviewSafety outcome
In patients with type 2 diabetes or obesity, tirzepatide was associated with a higher risk of cholelithiasis than comparators in a meta-analysis of randomized trials.
In plain wordsIn people with type 2 diabetes or obesity, tirzepatide was linked to more gallstones than placebo or other diabetes drugs.
Peptide
Tirzepatide
Outcome
IncreaseCholelithiasis
Study
n = 12,351
Comparator
Placebo or other hypoglycemic drugs
Outcome group
Biliary adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
risk ratio
1.67 RR
cholelithiasis
Source sentences
Summary
cholelithiasis (RR = 1.67; 95%CI: 1.14-2.44; I² = 0%, P = 0.95)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled studies (RCTs) investigating the safety of tirzepatide vs placebo/other hypoglycemic drugs in patients with T2DM or obesity were included.
Summary · context
A total of 12 high-quality RCTs (involving 12,351 patients) were included.
Report a problemFND-3956960602
03HumanSystematic reviewSafety outcome
In patients with type 2 diabetes or obesity, subgroup analysis found no dose-response relationship between tirzepatide doses and the risk of gallbladder/biliary diseases.
In plain wordsIn people with type 2 diabetes or obesity, higher tirzepatide doses were not linked to higher gallbladder and bile duct disease risk.
Peptide
Tirzepatide
Outcome
No significant changeDose-response for gallbladder/biliary diseases
Study
n = 12,351
Comparator
Placebo or other hypoglycemic drugs
Outcome group
Biliary adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis based on the dose of tirzepatide found no dose-response relationship between different doses of tirzepatide and the risk of gallbladder/biliary diseases and cholelithiasis.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled studies (RCTs) investigating the safety of tirzepatide vs placebo/other hypoglycemic drugs in patients with T2DM or obesity were included.
Summary · context
A total of 12 high-quality RCTs (involving 12,351 patients) were included.
Report a problemFND-3956960603
04HumanSystematic reviewSafety outcome
In patients with type 2 diabetes or obesity, subgroup analysis found no dose-response relationship between tirzepatide doses and the risk of cholelithiasis.
In plain wordsIn people with type 2 diabetes or obesity, higher tirzepatide doses were not linked to higher gallstone risk.
Peptide
Tirzepatide
Outcome
No significant changeDose-response for cholelithiasis
Study
n = 12,351
Comparator
Placebo or other hypoglycemic drugs
Outcome group
Biliary adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis based on the dose of tirzepatide found no dose-response relationship between different doses of tirzepatide and the risk of gallbladder/biliary diseases and cholelithiasis.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled studies (RCTs) investigating the safety of tirzepatide vs placebo/other hypoglycemic drugs in patients with T2DM or obesity were included.
Summary · context
A total of 12 high-quality RCTs (involving 12,351 patients) were included.
Report a problemFND-3956960604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.